 Connection
Ping-Ching Hsu to Mutation
This is a "connection" page, showing publications Ping-Ching Hsu has written about Mutation.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.148 |
|
|
|
-
Hsu PC, Chang JW, Chiu LC, Yang CT, Kuo SC, Fang YF, Wu CE. Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy. Clin Transl Oncol. 2025 May; 27(5):1967-1979.
Score: 0.584
-
Chang ZT, Hsu PC, Ko HW, Chang JW, Wu CT, Huang CY, Chang CF, Kuo CS, Yang CT, Wu CE. Baseline and changes in inflammatory parameters for patients with EGFR-mutated NSCLC treated with afatinib. Thorac Cancer. 2025 Jul; 16(13):e15338.
Score: 0.152
-
Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, Sanborn RE, Chih-Hsin Yang J, Liu B, John T, Massut? B, Spira AI, Lee SH, Wang J, Li J, Liu C, Novello S, Kondo M, Tamiya M, Korbenfeld E, Moskovitz M, Han JY, Alexander M, Joshi R, Felip E, Voon PJ, Danchaivijitr P, Hsu PC, Silva Melo Cruz FJ, Wehler T, Greillier L, Teixeira E, Nguyen D, Sabari JK, Qin A, Kowalski D, Sendur MAN, Xie J, Ghosh D, Alhadab A, Haddish-Berhane N, Clemens PL, Lorenzini P, Verheijen RB, Gamil M, Bauml JM, Baig M, Passaro A. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. J Clin Oncol. 2024 Oct 20; 42(30):3593-3605.
Score: 0.143
-
Wu CE, Chang CF, Huang CY, Yang CT, Kuo CS, Hsu PC, Chang JW. Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer. 2021 Jul 27; 21(1):859.
Score: 0.117
-
Hsu PC, Miao J, Huang Z, Yang YL, Xu Z, You J, Dai Y, Yeh CC, Chan G, Liu S, Urisman A, Yang CT, Jablons DM, You L. Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model. J Cell Mol Med. 2018 06; 22(6):3073-3085.
Score: 0.093
-
Lu CW, Pang JS, Ko YS, Chang CJ, Wang CW, Chen WT, Chen CB, Hui RC, Hung SI, Lu LY, Lu KL, Wang CL, Wu CE, Hsu PC, Fang YF, Li SH, Ko HW, Tseng LC, Shih FY, Chen MJ, Chung WH. Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma. J Eur Acad Dermatol Venereol. 2023 Feb; 37(2):328-339.
Score: 0.032
-
Lu CW, Wang TY, Yen CF, Chen KH, Wu CE, Wang CL, Hsu PC, Fang YF, Li SH, Ko HW, Tseng LC, Shih FY, Lin YJ, Chen MJ, Chen CB, Su Pang JH, Chung WH, Ko YS. Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a case-control cohort study. Int J Dermatol. 2021 Feb; 60(2):179-184.
Score: 0.028
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|